Loading...
Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
RCT
ACE Report #10382
Ace Report Cover Cannabis

Dronabinol does not cause metabolic disturbances in managing chronic neuropathy pain


Study Type:Therapy
OE Level Evidence:2
Journal Level of Evidence:N/A

A 4-week pilot study with the cannabinoid receptor agonist dronabinol and its effect on metabolic parameters in a randomized trial

Clin Ther. 2015 Oct 1;37(10):2267-74. doi: 10.1016/j.clinthera.2015.07.023

Contributing Authors: L Bayman J Valestin A Rizvi-Toner R Schey ZW Reichenbach J Sloan

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here

Synopsis

13 patients diagnosed with non-cardiac chest pain were randomly assigned to orally consume twice a day for 4 weeks either 5mg dronabinol capsules or placebo capsules. Metabolic parameters such as body mass index, various cholesterol levels, triglyceride level, plasma glucose level, insulin and leptin level, and high-sensitivity C-reactive protein level were assessed at the beginning and end of the...

To view the full report, start your 30-day free trial today

No credit card required

JOIN Forgot Password?

Not sure if you want to join OrthoEvidence?

Access this report without an Account.

Success, an email containing a link to access this report has been sent to your inbox.

CME Image

Continuing Medical Education Credits

You could be earning 0.5 CME credits for each report you read.

LEARN MORE

Please Login or Join to leave comments.